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Patients with HIV-associated tuberculosis (TB) initiating antiretroviral therapy (ART)
may develop immune reconstitution inﬂammatory syndrome (TB-IRIS). No biomarkers for
TB-IRIS have been identiﬁed and the underlying mechanisms are unclear. Here we perform
transcriptomic proﬁling of the blood samples of patients with HIV-associated TB. We identify
differentially abundant transcripts as early as week 0.5 post ART initiation that predict
downstream activation of proinﬂammatory cytokines in patients who progress to TB-IRIS. At
the characteristic time of TB-IRIS onset (week 2), the signature is characterized by over-
representation of innate immune mediators including TLR signalling and TREM-1 activation of
the inﬂammasome. In keeping with the transcriptional data, concentrations of plasma cyto-
kines and caspase-1/5 are elevated in TB-IRIS. Inhibition of MyD88 adaptor and group 1
caspases reduces secretion of cytokines including IL-1 in TB-IRIS patients. These data provide
insight on the pathogenesis of TB-IRIS and may assist the development of speciﬁc therapies.
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T
he World Health Organization (WHO) estimates that
approximately one-third of the world’s population is
infected with Mycobacterium tuberculosis (MTB),
5%–10% of whom will develop active disease1 with human
immunodeﬁciency virus type 1 (HIV-1) infection being the
greatest recognized risk factor for disease2. Seventy-eight per cent
of those with HIV-associated tuberculosis (TB) live in Africa1.
Increased access to combination antiretroviral therapy (ART) has
signiﬁcantly improved the clinical outcome of such patients in
resource-limited settings3,4. However, up to 54% of patients
develop hyperinﬂammatory reactions known as immune
reconstitution inﬂammatory syndrome (IRIS) within the ﬁrst
month of ART initiation5. Paradoxical TB-IRIS is directed
towards MTB antigens and is characterized by recurrent, new
or worsening symptoms and signs of treated TB.
Three clinical risk factors for HIV-associated paradoxical TB-
IRIS are recognized: (i) low baseline CD4þ T-cell count
(o50–100 cells per mm3) before ART6–8; (ii) a short time
interval between commencing TB treatment and ART6–8; and
(iii) dissemination of TB to extrapulmonary sites, possibly reﬂecting
higher bacterial load9,10. Nevertheless, the immunopathological
basis of the syndrome remains incompletely understood and there
is no biomarker to predict which patients will develop IRIS. Studies
to date have suggested that both innate and adaptive immunity are
involved, leading to hypercytokinemia and severe inﬂammation11.
Although hyperinﬂammation in TB-IRIS is associated with the
expansion of TB antigen-speciﬁc interferon-g (IFN-g) producing
peripheral T-helper 1 cells12, the absence of such expansion in
some TB-IRIS cases and the presence in similar patients who do
not develop the syndrome suggests that the association might not
be causal13. Several studies have suggested that innate immunity
also contributes to IRIS. In post-mortem staining of lung tissue
sections from a TB-IRIS patient, most of the inﬂammatory cells
were identiﬁed to be CD68þ macrophages14. Increased natural
killer cell activation and degranulation activity15,16, and elevated
neutrophil counts in the cerebrospinal ﬂuid17,18 of tuberculous
meningitis-IRIS cases have also been reported. The levels of
interleukin (IL)-6 and C-reactive protein are elevated at the time
of IRIS in both Mycobacterium avium-associated IRIS19 and
paradoxical TB-IRIS5,13,20. TB-IRIS patients were also reported to
have higher expression level of pattern recognition receptors
(PRRs) such as Toll-like receptor 2 (TLR2)15,21–23. Microarray
analysis of monocytes isolated from HIV-TB co-infected patients
suggested an imbalance between the complement effector C1q
and the inhibitor C1-INH in those who developed TB-IRIS24.
Notwithstanding these extensive research efforts, the underlying
mechanisms mediating TB-IRIS remain to be fully elucidated.
The application of systems immunology has signiﬁcantly
increased understanding of many diseases. In the last few years,
transcriptional proﬁling of blood from TB patients has led to the
ﬁnding of a type I IFN-inducible neutrophil-driven signature of
active TB disease25. In this study, we used a similar unbiased
whole-blood transcriptomic proﬁling of HIV-TB co-infected
patients commencing ART, to better understand the immune
pathways resulting in TB-IRIS. Patients were tracked
longitudinally to ascertain development of TB-IRIS. We
characterized plasma cytokine proﬁles, which were in keeping
with the transcriptomic signature. We further demonstrated the
dependence of elevated levels of cytokine on TLR signalling
pathways, as well as caspase-1-dependent canonical and caspase-
5-dependent non-canonical inﬂammasomes.
Results
Patient characteristics. Thirty-two patients with HIV-associated
TB were included for microarray analysis. Patients in both TB-IRIS
(n¼ 17) and non-IRIS (n¼ 15) groups had similar clinical
variables, including age, sex, CD4 count and HIV viral load, and
site of MTB infection (Supplementary Table 1). The majority of
patients had both pulmonary and extrapulmonary TB (PTB and
EPTB); the latter usually manifest as visceral TB, peripheral
adenopathy and pleural effusion, with only a few cases of tuber-
culous meningitis (n¼ 7). Patients who developed TB-IRIS had
symptom onset at a median of 13 days (interquartile range (IQR):
7–21 days) after ART initiation. An additional 31 patients were not
included in the microarray analysis, owing to lack of whole-blood
samples, but had plasma cytokines analysed. No signiﬁcant
differences were observed compared with the microarray group
with regard to clinical variables (Supplementary Table 1).
Differentially abundant transcripts at 2–5 days post ART.
Longitudinal whole-blood samples were collected from patients
with HIV-associated TB commencing ART (Fig. 1a). We
investigated the molecular path of immune dysregulation leading
to TB-IRIS by inspecting transcriptomic changes in TB-IRIS
and non-IRIS patients by using two different normalization
approaches. First was a modiﬁed method from one previously
described25,26, in which signal intensities were normalized to the
median of all samples. The second approach normalized each
sample to its corresponding baseline (week 0). Differentially
expressed genes identiﬁed by both approaches are listed in
Supplementary Table 2.
At week 0, there was no transcriptomic difference between
patients who did or did not develop TB-IRIS; however, within
2–5 days post ART (week 0.5) we identiﬁed 22 differentially
abundant transcripts (20 genes) in patients who developed
TB-IRIS (Fig. 1b) by using the normalization to median method.
Functional analysis of these 22 differentially abundant transcripts
indicated over-representation of the JAK/STAT signalling path-
ways mediated by the IL-6 cytokine family and a role for
macrophages and complement (Fig. 1b). Using the alternative
normalization to baseline approach, we further identiﬁed 56
differentially abundant transcripts (50 genes) in TB-IRIS patients
early during ART (week 0.5) (Fig. 1c). Innate immune pathways
remained dominant in TB-IRIS, represented by upregulated type
I and II IFN signalling, activation of PRRs and the role of
macrophages (Fig. 1c), although only 5 of the 50 genes overlapped
with the 20 genes identiﬁed using the normalization to median
approach. Together, the data suggest early activation of a
predominantly innate inﬂammatory response at transcriptomic
level in TB-IRIS before the onset of clinical symptoms.
Transcriptomic signature at the time of symptom onset.
Applying the same analytical approaches described above, we
identiﬁed a 138-transcript (125 gene) signature associated with
TB-IRIS at week 2 by normalizing to the median (Fig. 2a
and Supplementary Table 3). Functional analysis of these 125
differentially abundant transcripts indicated upregulation of
several innate response pathways, with TLR and TREM1-induced
inﬂammasome signalling being most over-represented (Fig. 2a),
again suggesting an important role of innate antigen recognition
and cytokine signalling in the inﬂammatory response in TB-IRIS.
When the transcriptional data were normalized to their
corresponding baseline values, we identiﬁed 319 transcripts
(281 genes) differentially abundant in TB-IRIS patients at week 2
(Fig. 2b and Supplementary Table 4). Functional pathway analysis
again indicated innate immune signalling pathways including
TLR, IFN and IL-1 signalling to be over-represented in TB-IRIS
(Fig. 2b). Of the 281 genes identiﬁed, 70 overlapped with the 125
genes identiﬁed by normalization to the median. The large
number of overlapping genes indicates they are conserved in
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TB-IRIS regardless of analytical method. Functional analysis of
the overlapping transcripts again indicated the innate immune
components, with TLR, TREM-1 and IL-1 being the most enri-
ched biological processes. Corticosteroid therapy was prescribed
in ten of the patients (four of whom had microarray performed)
at the time of ART commencement but it was not a confounding
factor in the transcriptomic analysis.
We next performed both regulator and molecule activity
prediction27 of the week 2 signature by using the 125 genes
identiﬁed by the normalization to median approach.
Proinﬂammatory cytokines including oncostatin M, IFN-g,
tumour necrosis factor (TNF) and IL-1 were predicted to be
the upstream regulators of the week 2 signature (Supplementary
Table 5). In addition, CSF-3 (granulocyte colony-stimulating
factor) and IL-5 were also predicted to be activated upstream at
week 2, suggesting activation of adaptive immunity. An array of
proinﬂammatory cytokines and chemokines were predicted to be
activated at week 2, including TNF-a, IL-1b, IL-6, IL-8, IL-12,
IL-18, granulocyte–macrophage colony-stimulating factor, mono-
cyte chemoattractant protein-1 and macrophage inﬂammatory
protein-2 (Fig. 3). Signalling appeared to be mediated by TLR and
IL-1/18 receptor via the MyD88 adaptor and TREM1-induced
activation of inﬂammasomes and TLR, resulting in the activation
of nuclear factor-kB and subsequent production of cytokines and
chemokines (Fig. 3).
Plasma cytokine measurement. As the transcriptomic signatures
predicted activation of many proinﬂammatory cytokines (Fig. 3),
we measured the concentration of these analytes in patient
plasma at both week 0 and week 2, to assess whether the
transcriptomic prediction was reﬂected in the blood protein.
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Figure 1 | Differentially abundant transcripts associated with progression to TB-IRIS were identiﬁed early before onset of clinical symptoms.
(a) Whole-blood samples were collected longitudinally and the median onset of TB-IRIS was 13 days. (b) Microarray was performed with 22 whole-blood
samples (13 TB-IRIS and 9 non-IRIS). Twenty-two transcripts (20 genes) were differentially abundant at week 0.5 (days 2–5 post ART) in those patients
who eventually developed TB-IRIS, compared with non-IRIS. Transcript intensity values were normalized to the median of all samples. Transcripts are
clustered vertically where green represents decreased abundance and red represents increased abundance. Patient arms are clustered horizontally where
blue represents non-IRIS and orange represent TB-IRIS. Signiﬁcance of pathways over-represented by differentially abundant genes was calculated by
Fisher’s exact test corrected for Benjamini–Hochberg false discovery rate (BH-FDR) (P¼0.05). (c) Using an alternative analytical approach by normalizing
transcript intensity to its corresponding baseline (week 0) value, 55 transcripts (50 genes) were found to be differentially abundant in TB-IRIS patients,
compared with non-IRIS controls. Signiﬁcance of pathways over-represented by differentially abundant genes was calculated by Fisher’s exact test
corrected for BH-FDR (P¼0.05). One sample was excluded from the analysis, owing to the lack of corresponding baseline.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9451 ARTICLE
NATURE COMMUNICATIONS | 6:8451 | DOI: 10.1038/ncomms9451 | www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
Week 2 (TB-IRIS onset) – normalized to median
Colour range
–4.4
Condition
Condition
(No TBIRIS)
(TBIRIS)
Color range
Condition
–3.9 0 3.9
Condition
(No TBIRIS)
(TBIRIS)
0 4.4
Week 2 (TB-IRIS onset) – normalized to baseline
Top 5 canonical pathways
TLR signalling
TREM1 signalling
Role of macrophages, fibroblasts and endothelial
cells in rheumatoid arthritis
Production of nitric oxide and reactive oxygen
species in macrophages
Role of pattern recognition receptors in
recognition of bacteria and viruses
Top 5 canonical pathways
TLR signalling
IFN signalling
Activation of IRF by cytosolic pattern
recognition receptor
IL-1 signalling
Role of pattern recognition receptors in
recognition of bacteria and viruses
1.29E–06
2.55E–05
2.62E–04
4.43E–04
8.99E–04
P-value
6.86E–07
2.85E–04
1.02E–03
1.47E–03
1.47E–03
P-value
a
b
Figure 2 | Differentially abundant transcripts in TB-IRIS onset are associated with innate signalling pathways. (a) Microarray was performed with 26
whole-blood samples (13 TB-IRIS and 13 non-IRIS). One hundred and thirty-eight transcripts (125 genes) were differentially abundant in the whole blood of
the TB-IRIS patients at week 2. Transcript intensity values were normalized to the median of all samples. Transcripts are clustered vertically where green
represents decreased abundance and red represents increased abundance. Patient arms are clustered horizontally where blue represents non-IRIS and
orange represent TB-IRIS. Signiﬁcance of pathways over-represented by differentially abundant genes was calculated by Fisher’s exact test corrected for
Benjamini–Hochberg false discovery rate (BH-FDR) (P¼0.05). (b) Using an alternative analytical approach by normalizing transcript intensity to its
corresponding baseline (week 0) value, 319 transcripts (281 genes) were found to be differentially abundant in TB-IRIS patients. Signiﬁcance of pathways
over-represented by differentially abundant genes was calculated by Fisher’s exact test corrected for BH-FDR (P¼0.05). One sample was excluded from
the analysis, owing to the lack of corresponding baseline.
Figure 3 | Transcriptomic signature of TB-IRIS at week 2 predicts activation of innate signalling pathways and production of proinﬂammatory
cytokines and chemokines. The TREM1, TLR and IL-1 signalling pathways are interconnected. Molecules in red were those found to be differentially
abundant in the signatures of TB-IRIS patients at week 2 (normalization to median). Molecule activity prediction was performed using Ingenuity Pathway
Analysis: molecules in orange were predicted to be upregulated and those in blue predicted to be downregulated.
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Congruent with the transcriptomic signature prediction of week
2, we detected signiﬁcantly higher concentrations of IL-12p40,
IFN-g, TNF-a and IL-6 in TB-IRIS patients at week 2 (Fig. 4),
indicating a circulating inﬂammatory response at the time when
clinical symptoms were observed. Our data agree with those
previously reported28, further indicating that TB-IRIS is strongly
associated with dysregulated cytokine and chemokine production.
Although IL-8 and type I IFN were also predicted to be elevated
at week 2, we did not detect any differences in plasma proteins
between non-IRIS and TB-IRIS patients (Fig. 4).
Validation by technically independent NanoString method. A
technically independent method, the NanoString (nCounter)
system, was used to further validate the 125 differentially
expressed genes identiﬁed at the median time of TB-IRIS onset
(week 2) by the standard normalization to median microarray
analytical approach (Fig. 2a). The 125 genes contained 70 genes
that were also identiﬁed using the alternative normalization to
baseline approach described above (Fig. 2b). Probes to sequences
differing from those detected by microarray were designed, with
one being excluded from the assay because of nonspeciﬁc
complementarity to other genes. Owing to insufﬁcient quantity of
RNA, eight samples (ﬁve TB-IRIS and three non-IRIS) were
excluded from the NanoString assay. Seventy-six of the 124 probes
that were statistically signiﬁcantly different in microarray were
also found signiﬁcant by NanoString (Supplementary Table 6).
The remaining 48 genes, although not statistically signiﬁcantly
different between the TB-IRIS and non-IRIS groups, also showed
the same trends in abundance as the microarray. The most over-
represented functional pathways of the 76 genes that were sig-
niﬁcantly upregulated in the TB-IRIS group were again from the
innate immune pathways: TLR, TREM1 and IL-1 signalling.
A 43-transcript signature that characterizes TB-IRIS. To
determine a signature that consisted only of the most conserved
genes differentially abundant across all technical or analytical
approaches, we overlapped the genes identiﬁed at week 2 in all
three approaches, resulting in a 43-transcript signature. Func-
tional analysis indicated over-representation of several innate
immune signalling pathways, including TREM-1 (P¼ 0.0002),
TLR (P¼ 0.0002), IL-1 (P¼ 0.0009) and type I IFN (P¼ 0.0022)
(Fig. 5). A ‘weighted temporal molecular distance’ algorithm was
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Figure 4 | Cytokine production at week 2 of TB-IRIS reﬂects the transcriptomic prediction. Plasma cytokine concentrations in TB-IRIS and non-IRIS
patients at week 0 and week 2 were measured. Results were analysed by Mann–Whitney U-test between non-IRIS and TB-IRIS at each time point. The
median value of each group was shown and P-value was designated: *Pr0.05, **Pr0.01.
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further applied to quantify changes in abundance of these 43
transcripts over time (Fig. 5). The weighted temporal molecular
distance algorithm measures the transcriptional perturbation of
speciﬁed genes at a given time point relative to the mean at week
0. The non-IRIS patients had no signiﬁcant changes in the level of
the 43 genes at week 0, 0.5, 1 or 2. By contrast, there was sig-
niﬁcant transcriptional perturbation at week 2 in TB-IRIS
patients compared with week 0 (P¼ 0.0268). Furthermore, there
was a signiﬁcant difference in the transcript levels of these 43
transcripts between the TB-IRIS and the non-IRIS patients as
early as 2–5 days post ART (week 0.5; P¼ 0.008), before IRIS-
associated clinical symptoms were apparent, suggesting that these
genes are speciﬁcally associated with, and represent the earliest
pathways involved in triggering clinical progression to, TB-IRIS.
Inhibition of MyD88 reduces proinﬂammatory cytokines. To
conﬁrm the involvement of TLRs in the induction of cytokines
that associate with TB-IRIS, we performed inhibition of the TLR
signalling pathway. We chose to inhibit MyD88 in peripheral
blood mononuclear cells (PBMCs) from both TB-IRIS and non-
IRIS patients using a speciﬁc peptide inhibitor (Pepinh-MYD),
compared with using a control peptide and RPMI medium
control (mock).
Among the analytes measured, concentrations of IL-12p40,
IFN-g and TNF-a in PBMC culture supernatant from TB-IRIS
patients signiﬁcantly decreased following treatment with MyD88
inhibitor, but not with the control peptide, compared with the
RPMI mock (Fig. 6). The same experiments were also performed
in the PBMCs from non-IRIS patients, but analytes were below
the limits of detection. Similar observations have also been
previously reported in the PBMCs from non-IRIS patients28.
Although IL-1 was predicted to be activated downstream of the
TLR-MyD88 signalling cascade, we failed to detect any difference
in the level of IL-1b following MyD88 inhibition (Fig. 6),
suggesting other immunological pathways are also involved in
mediating the inﬂammatory response in TB-IRIS.
Inﬂammasomes mediate proinﬂammatory responses in TB-IRIS.
We next investigated TREM1 signalling, the other consistently over-
represented pathway in TB-IRIS. The TREM1 activation in TB-IRIS
consisted of upregulated messenger RNA expression of TLRs, NLR,
NOD, CARD and CASP5 (caspase-5), all of which are involved in
canonical and non-canonical inﬂammasomes. We detected a
signiﬁcantly higher concentration of caspase-1 in the supernatant of
MTB-stimulated PBMC cultures from TB-IRIS patients at week 2
(Fig. 7a), suggesting the canonical inﬂammasome may be involved in
mediating TB-IRIS. For the non-canonical inﬂammasome, PBMC
lysates from TB-IRIS were found to have a signiﬁcantly higher
content of caspase-5, compared with non-IRIS (Fig. 7a), indicating
that the non-canonical inﬂammasome is also activated during
TB-IRIS. There was no signiﬁcant difference in the anti-inﬂamma-
tory apoptotic caspase-3 between TB-IRIS and non-IRIS (Fig. 7a).
We next quantiﬁed the concentration of IL-1b and IL-1a in tissue
culture (TC) supernatant as they are cleaved by caspase-1 and cas-
pase-5, respectively. Signiﬁcantly higher concentrations of IL-1b and
IL-1a were detected in TB-IRIS, compared with non-IRIS (Fig. 7b).
Treatment with an irreversible pan-caspase-1/4/5 inhibitor
Z-WEHD-FMK signiﬁcantly reduced the production of IL-1b and
IL-1a in both groups, with a greater reduction observed in TB-IRIS.
Together, these data suggest that inﬂammasome activation also
contributes to the inﬂammatory response in TB-IRIS.
Discussion
We have identiﬁed differentially abundant transcripts that
characterize patients who develop TB-IRIS from those that do
not as early as week 0.5 (days 2–5) following ART initiation,
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Figure 5 | Weighted temporal molecular distance to health of 43 consistently overabundant transcripts differentiate TB-IRIS patients from non-IRIS
controls. Forty-three genes were consistently overabundant in TB-IRIS by different analytical and technical platforms. These genes are associated with
innate signalling pathways, namely TREM1, TLR and IL-1 signalling (Fisher’s exact test with Benjamini–Hochberg false discovery rate (BH-FDR), P¼0.05).
The weighted temporal molecular distance measured the total transcriptional perturbation of the 43 genes at each time point relative to its baseline (week
0) mean. The mean, s.e.m. and P-values are displayed (unpaired t-test with Welch’s correction; *Pr0.05 and **Pr0.01).
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Figure 7 | Both canonical and non-canonical inﬂammasomes are activated in TB-IRIS. (a) Patient PBMC from TB-IRIS and non-IRIS (week 2) were
treated with pan-group 1 caspase inhibitor or dimethyl sulfoxide (DMSO) vehicle control, followed by stimulation with heat-inactivated H37Rv. An
unstimulated background control was included for each treatment per sample. Concentrations of caspase-1 (left, on TC supernatant) and caspase-3 (right,
with lysate) are shown as background subtracted (stimulated minus unstimulated) with a value of zero assigned to those negative after background
subtraction. Caspase-5 (middle, with lysate) is expressed as fold-change of stimulated samples over unstimulated controls, as a standard curve was not
available. The Wilcoxon signed rank test was used for statistical comparisons. The median value of each group was shown and P-value was designated:
*Pr0.05, **Pr0.01, ***Pr0.001 and ****Pr0.0001. (b) Reﬂecting increased concentrations of caspase-1 and caspase-5, concentrations of IL-1b (left)
and IL-1a (right) produced by patient PBMCs treated above were measured. Concentrations are expressed as that from MTB-stimulated minus the
corresponding unstimulated control.
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indicating an early transcriptional response before clinical
symptoms. These early changes were predominantly related to
enriched JAK/STAT signalling pathways mediated by either IL-6
or type I and II IFNs, as well as activation of PRRs and a role of
macrophages via IL-1/18R, indicating the restoration of an innate
immune response immediately following ART initiation.
Although IL-1, IL-6, TNFa and IFN-g have all been shown to
be important in protection against MTB29–33, type I IFN may
adversely affect the host immune response34. The transcriptomic
signature of TB patients is characterized by a neutrophil-driven
type I IFN-inducible response, which correlates with lung
radiographic extent of disease and is downregulated on
successful treatment25. Furthermore, in chronic MTB or
Mycobacterium leprae infection, type I IFN plays an
immunosuppressive role by inducing IL-10 and PDL1, and
suppressing the production of IL-1a and IL-1b (refs 30,35–38).
This inﬂammatory equilibrium of type I IFN appears to be
disrupted in TB-IRIS, in which the negative feedback was not
sufﬁcient to control the downstream activation of the
proinﬂammatory response, as we observed increased plasma
concentration of IL-12p40 and enhanced secretion of IL-1a and
IL-1b in PBMC cultures from TB-IRIS patients.
Of relevance, we also found that early differentially abundant
transcripts in TB-IRIS predicted activation of nuclear factor-kB
and p38-MAPK signalling pathways, and the production of
proinﬂammatory cytokines and chemokines. The molecules of the
week 0.5 signatures were also found to be upstream of the week 2
signatures. Indeed, we detected elevated plasma concentrations of
some of these proinﬂammatory cytokines in TB-IRIS patients at
week 2, compared with non-IRIS controls. These results are in
agreement with our previous studies on TB-IRIS18,28,39,40.
We hypothesize that TB-IRIS arises from a combination of a
high MTB antigen load at ART initiation17 and differential
antigen recognition and immune signalling by innate immune
receptors after ART initiation in TB-IRIS patients, which in turn
contributes to hypercytokinemia and inﬂammation. Both TLR
and IL-1R (Toll/IL-1 receptor (TIR)) share a 200-residue
intracellular domain and activate a Rel-type transcription factor
on stimulation41. In synergy with TIR, TREM1 modulates the
production of cytokines and chemokines, and ampliﬁes the
proinﬂammatory response induced by TIRs42. Following bacterial
sensing, TREM1 signals to activate downstream inﬂammasome
activity43. MTB has been shown to activate caspase-1-dependent
NLRP3 canonical inﬂammasome during infection that
contributes to damaging innate inﬂammatory responses44,45.
More recently, a non-canonical inﬂammasome has been
described in Gram-negative bacterial infection that activates
caspase-11 in mice (orthologue of caspase-4/5 in humans)
through a lipopolysaccharide-dependent pathway46,47. Although
MTB does not contain lipopolysaccharide, the bacilli have lipid-
rich cell walls that contain complex glycosylated lipids, mycolic
acids and acylated lipids, among others, and are readily sensed by
TLR4 in response to infection48,49. We speculate that MTB may
feasibly modulate the activity of non-canonical inﬂammasomes,
as signiﬁcantly higher levels of caspase-1 and caspase-5, and their
prototypic cytokines IL-1b and IL-1a, were detected in PBMCs
from TB-IRIS patients stimulated with heat-inactivated MTB,
compared with the non-IRIS counterparts. A pan-group 1 caspase
inhibitor, Z-WEHD-FMK, signiﬁcantly reduced production of
IL-1a and IL-1b, with a particularly prominent effect observed in
TB-IRIS (Fig. 7), further indicating that the proinﬂammatory
response in TB-IRIS is at least in part mediated by
inﬂammasomes. It is established that TLRs and inﬂammasome
signals converge to amplify the innate immune response50. More
recently, this convergence in signalling has also been shown to
amplify CD4þ T-cell effector functions in bacterial pathogen
clearance in a MyD88-dependent manner51. With the exception
of TLR3, all other TLRs and IL-1R signal through the MyD88
adaptor. Inhibition of the MyD88 in PBMCs from TB-IRIS
patients signiﬁcantly reduced the production of proinﬂammatory
cytokines (Fig. 6), indicating that a TLR-MyD88 signalling
pathway contributes to the dysregulated cytokine response in
TB-IRIS. Interestingly, PBMCs from the non-IRIS patients
produced minimal levels of IFN-a, IFN-g, IP-10 and IL-12,
following stimulation, and inhibition of the MyD88 adaptor did
not reduce production of other cytokines/chemokines, further
suggesting that the dysregulated cytokine/chemokine production
via MyD88 signalling contributes to TB-IRIS. Together, our data
provide good evidence that inﬂammation and subsequent T-cell
expansion in TB-IRIS is driven by innate immune signalling and
its ampliﬁcation, which triggers the activation of transcriptional
factors, with the end result being hypercytokinemia contributing
to systemic inﬂammation.
Two recent studies on TB-IRIS also investigated the role of
innate immunity via microarray analysis of blood monocytes24,52.
A few of the differentially expressed genes in TB-IRIS from these
studies were also identiﬁed in ours, which used whole blood. The
authors of these studies also reported PRRs, the complement
system and communication between innate and adaptive
immunity as among the most signiﬁcantly upregulated
pathways, further suggesting a prominent contribution of innate
immunity to the pathogenesis of TB-IRIS.
Prednisone is used for the treatment of TB-IRIS and has
been demonstrated in a clinical trial, to result in more rapid
clinical improvement53. However, corticosteroids have potential
side effects in patients with advanced HIV-related immuno-
suppression such as the development of herpes zoster and
Kaposi’s sarcoma54,55, and therefore therapeutic strategies that
offer greater immune speciﬁcity should be explored. We
acknowledge that our sample size is small and our ﬁndings
require further validation; nevertheless, the ability to identify a
transcriptomic signature of TB-IRIS within days of commencing
ART may be beneﬁcial in directing preventive interventions in
the absence of a pre-ART predictive biomarker. We have
demonstrated that blocking MyD88 and group 1 caspases
reduced the production of proinﬂammatory cytokines in
TB-IRIS. Based on our ﬁndings, we postulate that immuno-
modulators have the potential to interrupt the inﬂammatory
pathways that lead to TB-IRIS and their utility as part of the
prevention strategies of TB-IRIS could be explored in future
studies. Anti-inﬂammatory agents that suppress innate signalling
networks are currently being evaluated in clinical trials as
treatment options for autoimmune diseases56. An anti-IL-1b
monoclonal antibody (canakinumab) is approved for use in
autoinﬂammatory syndromes and recombinant IL-1R antagonist
(anakinra) for rheumatoid arthritis, suggesting a potential role for
these drugs in other inﬂammatory conditions. HIV-TB coinfected
patients who display an early transcriptomic signature associated
with an increased risk of developing TB-IRIS may potentially
beneﬁt most from such pre-emptive therapies. In this respect,
the recent description of MCC950 (ref. 57), a potent, selective,
small-molecule inhibitor of NLRP3, is of particular interest.
Methods
Ethical approval. The University of Cape Town’s Faculty of Health Sciences
Research Ethics Committee approved this study (HREC No: 049/2009). All
participants provided written informed consent.
Study design and participant recruitment. Hospitalized patients with
HIV-associated TB were recruited to a prospective, observational cohort study at
Brooklyn Chest Hospital (Cape Town, South Africa) between April 2009 and
December 2010 (refs 39,58). Eligible patients were adults older than 18 years of age
with serologically conﬁrmed HIV-1 infection and a diagnosis of PTB and/or EPTB.
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Patients were ART naive at the time of recruitment and started ART according to
WHO guidelines (CD4 counto200 cells per mm3 or WHO stage 4 deﬁning illness
before March 2010 and CD4 counto350 cells per mm3 or WHO stage 4 deﬁning
illness thereafter). Exclusion criteria included patients with known rifampicin-
resistant TB and inability to provide consent. We selected the ﬁrst 32 patients
(17 TB-IRIS and 15 non-IRIS) enroled, from whom longitudinal Tempus blood
samples were available to undertake microarray analysis. We further included
another 31 patients (16 TB-IRIS and 15 non-IRIS) to analyse plasma proteins and
investigate potential mechanisms mediating TB-IRIS. All but one patient, who was
prescribed nevirapine, received efavirenz-based non-nucleoside reverse-
transcriptase inhibitor containing ART regimens. Ten patients (four TB-IRIS and
six non-IRIS) were on corticosteroid therapy when they commenced ART for an
average of 41 days. Corticosteroids were prescribed to most participants who were
diagnosed with TB-IRIS.
Case deﬁnitions. TB was diagnosed on the basis of smear or culture positivity.
Where this was negative or unavailable, diagnosis was according to WHO guide-
lines for diagnosis of smear negative or EPTB in HIV-1-infected persons59.
TB-IRIS was diagnosed according to the International Network for the Study of
HIV-associated IRIS case deﬁnition60. TB-IRIS patients typically displayed
systemic and/or local inﬂammatory features including fever, weight loss,
tachycardia, lymphadenitis, enlarging serous effusions and new or recurrent
inﬁltrates on chest radiographs60. Non-IRIS patients were deﬁned as those free of
IRIS symptoms during the 3-month follow-up period.
Blood sample collection and processing. Whole blood was collected in sodium-
heparin and Tempus tubes (Life Technologies, Carlsbad, CA) longitudinally at four
different timepoints: week 0 before initiation of ART and weeks 0.5 (2–5 days post-
ART), 1 and 2 for both TB-IRIS and non-IRIS patients post ART. Except for
patients who were already receiving corticosteroids at the time of ART initiation,
all other patient blood samples before and at week 2 were taken before initiation of
corticosteroid therapy. Plasma and PBMCs were separated from whole blood
collected in sodium-heparin using Ficoll-Paque (Pharmacia Biotech, Uppsala,
Sweden) according to the manufacturer’s protocol. Plasma was stored at  80 C
and PBMCs were stored in the vapour phase of liquid nitrogen until use. Whole-
blood and plasma samples were not available for all time points in some patients
because of their discharge or transfer.
RNA extraction and processing for microarray analysis. RNA was extracted
from whole blood in Tempus tubes using the MagMAX for Stabilized Blood Tubes
RNA Isolation kit (Life Technologies) according to the manufacturer’s instructions.
Total RNA (2.5 mg) was then globin reduced using the GLOBINclear 96-well plate
format kit (Life Technologies). The total RNA yield after globin reduction was
determined in a NanoDrop 1,000 spectrophotometer (Fisher Scientiﬁc, Waltham,
MA) and integrity assessed by Agilent 2,100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). Samples with RNA integrity number 46.0 were determined to
be of acceptable quality for further analysis. Approximately 250 ng of globin-
reduced RNA was used to prepare ampliﬁed and biotinylated antisense com-
plementary RNA targets using the Illumina TotalPrep RNA ampliﬁcation kit (Life
Technologies). Seven hundred and ﬁfty nanograms of labelled cRNA was hybri-
dized overnight to Illumina human HT-12 v4 BeadChip arrays (Illumina Inc., San
Diego, CA), which contained 447,000 probes (transcripts). Some genes were
represented by more than one probe (transcript). The arrays were then washed,
blocked, stained and scanned on an Illumina BeadStation 500. Signal intensity
values from the scans were generated by the Illumina BeadStudio v2 software. All
samples were randomized during all stages of processing to avoid any batch effect.
Microarray data analysis. A detail ﬂow diagram on the analytical strategy is
shown in Supplementary Fig. 1. Raw microarray data were background subtracted
and scaled data were generated using Illumina BeadStudio v2 software. A stringent
ﬁlter was implemented to select only those transcripts present in 100% of all
samples in either the IRIS or the non-IRIS group. The transcripts were further
selected to have Z2-fold expression change compared with the non-IRIS samples.
The Mann–Whitney U-test was applied and corrected with asymptotic Benjamini–
Hochberg false discovery rate set at P¼ 0.05. The identiﬁed transcripts were then
clustered using a hierarchical algorithm with Pearson’s uncentred distance metric
and average linkage.
Canonical pathway, upstream regulator and molecule activity prediction of
differentially abundant transcripts were analysed by Ingenuity Pathway Analysis
(Ingenuity Systems, www.ingenuity.com). The signiﬁcance (P-value) of association
between the transcripts and the pathway was calculated using Fisher’s exact test of
probability. The weighted temporal molecular distance was determined for each
time point as previously described61, except that the mean baseline value of each
group was used as a control. Brieﬂy, the algorithm determined whether the raw
expression value of each differentially expressed transcript in each sample lay
within or outside two s.d. of the baseline mean. To qualify, transcripts had to differ
by at least 200 units in raw signal intensity and 2 s.d. from the baseline mean. The
weighted distance is the group mean of the sum of the total s.d. for all qualifying
transcripts in each sample in each patient.
NanoString. Differentially abundant transcripts identiﬁed by microarray analysis
were reinvestigated and validated using a customized NanoString nCounter assay
(NanoString Technologies, Seattle, WA)62. Housekeeping genes (n¼ 9) and
customized barcoded capture/reporter probe pairs speciﬁc for each transcript
(n¼ 124) were hybridized overnight at 65 C to 100 ng of total RNA samples
previously used in microarray. Six additional positive and negative control probe
pairs were also included. Unhybridized probes were removed and the hybridized
probes were puriﬁed on an nCounter Prep Station. The barcode on each reporter
probe was scanned with an nCounter Digital Analyzer to generate a quantitative
measure of the hybridized RNA. Sample signal values were background subtracted
and normalized ﬁrst to the positive control spikes and then to housekeeping genes.
Ninety-nine of the 107 samples from week 0, 0.5, 1 and 2 were included when
sufﬁcient RNA was available.
Plasma protein determination. The plasma concentrations of 18 cytokines and
chemokines were measured in 33 TB-IRIS and 30 non-IRIS patients in week 0 and
week 2 samples. TNF-a, IFN-g, IFN-a2 and IL-1b, IL-6, IL-8 and IL-12p40 were
quantiﬁed on the Bio-Plex platform (Bio-Rad Laboratories, Hercules, CA), using
customized Milliplex kits (HCYTMAG-60K, Merck Millipore, Germany). The
concentration of IL-1a was measured by enzyme-linked immunorsorbent assay
(eBioscience, San Diego, CA).
MyD88 inhibition assay. PBMCs from 13 TB-IRIS and non-IRIS patients (week
2, microarrayed) were defrosted and rested overnight at 37 C in RPMI with 10%
FCS. Total cell number was counted using a Coulter Counter (Beckman, Brea, CA)
and cell viability was determined by Trypan blue staining in a TC-20 automatic cell
counter (Bio-Rad, Hercules, CA). Lyophilized MyD88 peptide inhibitor (Pepinh-
MYD; InvivoGen, San Diego, CA) and a control peptide (Pepinh-Control; Invi-
voGen) were dissolved in endotoxin-free water at 1mM stock concentration.
PBMCs were treated with MyD88 peptide inhibitor (50 mM), control peptide
(50 mM) or RPMI mock for 5 h at 37 C. Samples were either stimulated or
unstimulated with heat-inactivated MTB (H37Rv; multiplicity of infection 1:1)
overnight at 37 C. TC supernatant was harvested and puriﬁed by centrifugation
twice at 2,000 r.p.m. and stored at  80 C until use. Cytokine concentrations in
supernatants were quantiﬁed by Luminex analysis. Heat-inactivated H37Rv was
used, because patients had undergone intensive antibiotic therapy at the time of
sampling and any antigens present would probably be bacterial fragments rather
than actively replicating bacilli.
Group 1 caspase inhibition assay. PBMCs from 16 TB-IRIS and 15 non-IRIS
patients (week 2, non-microarrayed) were thawed, rested and counted as above.
Lyophilized caspase-1/4/5 irreversible peptide inhibitor (Z-WEHD-FMK; R&D
Systems, Minneapolis, MN) was dissolved in dimethyl sulfoxide at 1mM stock
concentration. PBMCs were treated with the Z-WEHD-FMK peptide inhibitor
(50 mM) or dimethyl sulfoxide vehicle control (50 mM) for 1 h at 37 C. Supernatant
was then removed and replenished with a fresh stock of RPMI supplemented with
10% FCS. Samples were either stimulated or unstimulated with heat-inactivated
MTB (H37Rv; multiplicity of infection 1:1) overnight at 37 C. TC supernatant was
harvested and puriﬁed by centrifugations twice at 2,000 r.p.m. The residual PBMC
pellets were lysed in lysis buffer on ice for 1 h and recentrifuged to remove all cell
debris. Cytokine concentrations in supernatants were quantiﬁed by Luminex assay.
Concentrations of caspase-1 (R&D Systems) and IL-1a (eBioscience) in super-
natant and caspase-3 (eBioscience) and caspase-5 (BioVision, Milpitas, CA) in
PBMC lysate were measured by enzyme-linked immunorsorbent assay. The activity
of caspase-5 was expressed as the fold change in absorbance (OD405nm) in MTB-
stimulated over unstimulated PBMC lysate, as recombinant protein standards were
not supplied in the assay kit.
Statistical analysis. Statistical analyses were performed in GraphPad Prism 6.0
software. Patient baseline characteristics were compared by w2-test for contingency
data or Kruskal–Wallis test for continuous data. The weighted temporal molecular
distance between IRIS and non-IRIS patients was compared using the unpaired
t-test with Welch’s correction. Differences in cytokine concentrations between
patient or treatment groups were compared by Mann–Whitney U- test or
Wilcoxon signed rank test for paired data. Potential signiﬁcance was inferred for
results associated with a P-value ofr0.05. Microarray data and canonical pathway
analysis were corrected for multiple testing using Benjamini–Hochberg false
discovery rate with q¼ 0.05.
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